---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000053"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-04-08T23:59:59+00:00"
generated_at: "2026-05-23T19:01:43.869139+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nurix posts Q1 FY2025 net loss $56.4M; bexobrutideg gets orphan drug designation

## Summary
- Revenue $18.5M, up from $16.6M YoY; net loss $56.4M ($0.67/share) vs $41.5M prior year.
- Cash & marketable securities $549.7M at Feb 28, 2025; down from $609.6M at Nov 30, 2024.
- Earned $7M milestones in quarter; post-quarter received $15M license extension fee from Sanofi.
- NX-5948 named bexobrutideg; FDA Orphan Drug for Waldenström macroglobulinemia; pivotal trials in CLL on track for 2025.
- Added Roy Baynes to board and John Northcott as CCO; Sanofi exercised option to license undisclosed inflammation target.

## SEC filing metadata
- accession: 0001549595-25-000053
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-04-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000053/0001549595-25-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000053/nrix-20250408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000053
- JSON: https://secwatch.observer/filing/0001549595-25-000053.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.